Lionco(SH:603669)2015-10-27 16:00Financial Performance - Operating income for the first nine months decreased by 4.65% to CNY 371,000,833.28 compared to the same period last year[6] - Net profit attributable to shareholders increased by 5.68% to CNY 100,011,254.46 for the first nine months[6] - The company achieved a net profit of CNY 28,630,600 in the third quarter, a year-on-year increase of 22.66%[10] - Total operating revenue for Q3 2015 was RMB 125,904,670.42, a slight increase of 1.6% compared to RMB 123,912,858.15 in Q3 2014[33] - Year-to-date operating revenue from January to September 2015 was RMB 371,000,833.28, down 4.6% from RMB 389,110,626.43 in the same period last year[33] - Year-to-date net profit for the first nine months of 2015 was RMB 100,011,254.46, an increase of 5.4% compared to RMB 94,637,294.32 in the previous year[34] - The net profit for Q3 2015 was approximately ¥32.02 million, compared to ¥165.65 million in Q3 2014, reflecting a significant decline[39] Assets and Liabilities - Total assets increased by 130.39% to CNY 1,289,778,847.25 compared to the end of the previous year[6] - Total liabilities were CNY 219,937,101.84, increasing from CNY 185,702,806.89[28] - Owner's equity reached CNY 1,069,841,745.41, significantly up from CNY 374,130,822.45[28] - Current assets totaled CNY 903,730,245.41, up from CNY 184,271,495.17 at the start of the year[27] - Non-current assets amounted to CNY 386,048,601.84, compared to CNY 375,562,134.17 previously[27] Cash Flow - The company reported a decrease of 23.75% in net cash flow from operating activities to CNY 79,076,599.09 for the first nine months[6] - Cash flow from operating activities for the first nine months of 2015 was ¥435.73 million, down from ¥507.89 million in the previous year[40] - The net cash flow from operating activities for the first nine months was ¥79.08 million, a decrease from ¥103.70 million in the same period last year[41] - Cash flow from financing activities for the first nine months of 2015 was ¥668.46 million, a significant increase from a net outflow of ¥104.73 million in the same period last year[41] - The ending cash and cash equivalents balance as of the end of the reporting period was ¥157.20 million, compared to ¥34.66 million at the end of the previous year[41] Shareholder Information - The total number of shareholders as of the report date was 28,531[13] - Zhejiang Lingkang Holdings held 49.50% of shares, with 128.7 million shares, making it the largest shareholder[13] - The company has committed to not transferring or selling shares for 36 months post-IPO, ensuring stability in shareholding[19] Research and Development - Research and development investment for the first nine months of 2015 was 23.36 million yuan, representing 6.30% of operating income[12] - The company plans to establish the Tibet Modern Tibetan Medicine Research Institute to enhance traditional Tibetan medicine using modern scientific concepts and technologies[12] Sales and Marketing - The top-selling drug, Injection Amino Acid Glutamine, generated sales of CNY 31,285,400, accounting for 24.85% of total sales[11] - The company's key product sales for the July-September period reached 87.63 million yuan, accounting for 69.61% of total sales, with the top eight products growing by 2.47% year-on-year[12] - Sales expenses decreased by 31.34% to 36.90 million yuan, primarily due to reduced marketing activities in certain provinces[16] Investment Activities - The company reported a net cash outflow from investing activities of approximately ¥648.27 million for the first nine months of 2015, compared to a net outflow of ¥60.87 million in the previous year[41] - The company received cash from investment absorption amounting to ¥717.87 million during the first nine months of 2015[41] - Total cash inflow from investment activities was ¥240,000,000.00, compared to ¥190,000,000.00 in the previous year, indicating a year-over-year increase of about 26.3%[42]